NVO - Ozempic Ingredient Gives Novo Nordisk's Kidney Trial A Positive Result: What It Means For Health Care | Benzinga
Novo Nordisk A/S (NYSE: NVO) shares got a boost this week after the drugmaker halted trials testing potential treatment for kidney failure on early signs of efficacy.
The study has implications for other drugmakers including Eli Lilly And Co (NYSE: LLY) and DaVita Inc (NYSE: DVA).
What To Know: The Independent Data Monitoring Committee recommended Novo Nordisk cut its kidney outcomes trial FLOW short after interim analysis showed the treatment was sure to succeed. The trial was halted close to a year ahead of schedule.
The trial tested whether semaglutide could delay the progression of chronic kidney disease. Semaglutide is the active ingredient in Ozempic, Novo Nordisk's diabetes drug. It's also ...